91制片厂

Published on Market Research Reports庐 Inc. ()

Home > Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Research Report 2023

Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Research Report 2023

Publication ID: 
PB504245486
Publication Date: 
May 10, 2023
Pages: 
90
Publisher: 
MRRPB5
Countries: 
Global [1]
USD 2,900.00

Please choose the suitable license type from above. More details are given under tab "Report License Types" below.

Healthcare [2]
Pharma & Healthcare [3]
Description: 

Highlights
The global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections include Eli Lily, Wockhardt Ltd, Amprologix Ltd, CrystalGenomics Inc, Debiopharm International SA, Destiny Pharma Plc, Lysimmune BioScience, Roivant Sciences Ltd and TGV-Inhalonix Inc, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections.
The Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Eli Lily
Wockhardt Ltd
Amprologix Ltd
CrystalGenomics Inc
Debiopharm International SA
Destiny Pharma Plc
Lysimmune BioScience
Roivant Sciences Ltd
TGV-Inhalonix Inc
Therapeutic Systems Research Laboratories Inc
Segment by Type
Injection
Pills
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents: 

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Injection
1.2.3 Pills
1.3 Market by Application
1.3.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Perspective (2018-2029)
2.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Growth Trends by Region
2.2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Historic Market Size by Region (2018-2023)
2.2.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecasted Market Size by Region (2024-2029)
2.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Dynamics
2.3.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Trends
2.3.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Drivers
2.3.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Challenges
2.3.4 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Players by Revenue
3.1.1 Global Top Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Players by Revenue (2018-2023)
3.1.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Players (2018-2023)
3.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue
3.4 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Concentration Ratio
3.4.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in 2022
3.5 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Key Players Head office and Area Served
3.6 Key Players Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Solution and Service
3.7 Date of Enter into Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Breakdown Data by Type
4.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Historic Market Size by Type (2018-2023)
4.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecasted Market Size by Type (2024-2029)
5 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Breakdown Data by Application
5.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Historic Market Size by Application (2018-2023)
5.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (2018-2029)
6.2 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2018-2023)
6.4 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (2018-2029)
7.2 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2018-2023)
7.4 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (2018-2029)
8.2 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Region (2018-2023)
8.4 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (2018-2029)
9.2 Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2018-2023)
9.4 Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (2018-2029)
10.2 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2018-2023)
10.4 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lily
11.1.1 Eli Lily Company Detail
11.1.2 Eli Lily Business Overview
11.1.3 Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.1.4 Eli Lily Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2018-2023)
11.1.5 Eli Lily Recent Development
11.2 Wockhardt Ltd
11.2.1 Wockhardt Ltd Company Detail
11.2.2 Wockhardt Ltd Business Overview
11.2.3 Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.2.4 Wockhardt Ltd Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2018-2023)
11.2.5 Wockhardt Ltd Recent Development
11.3 Amprologix Ltd
11.3.1 Amprologix Ltd Company Detail
11.3.2 Amprologix Ltd Business Overview
11.3.3 Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.3.4 Amprologix Ltd Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2018-2023)
11.3.5 Amprologix Ltd Recent Development
11.4 CrystalGenomics Inc
11.4.1 CrystalGenomics Inc Company Detail
11.4.2 CrystalGenomics Inc Business Overview
11.4.3 CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.4.4 CrystalGenomics Inc Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2018-2023)
11.4.5 CrystalGenomics Inc Recent Development
11.5 Debiopharm International SA
11.5.1 Debiopharm International SA Company Detail
11.5.2 Debiopharm International SA Business Overview
11.5.3 Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.5.4 Debiopharm International SA Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2018-2023)
11.5.5 Debiopharm International SA Recent Development
11.6 Destiny Pharma Plc
11.6.1 Destiny Pharma Plc Company Detail
11.6.2 Destiny Pharma Plc Business Overview
11.6.3 Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.6.4 Destiny Pharma Plc Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2018-2023)
11.6.5 Destiny Pharma Plc Recent Development
11.7 Lysimmune BioScience
11.7.1 Lysimmune BioScience Company Detail
11.7.2 Lysimmune BioScience Business Overview
11.7.3 Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.7.4 Lysimmune BioScience Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2018-2023)
11.7.5 Lysimmune BioScience Recent Development
11.8 Roivant Sciences Ltd
11.8.1 Roivant Sciences Ltd Company Detail
11.8.2 Roivant Sciences Ltd Business Overview
11.8.3 Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.8.4 Roivant Sciences Ltd Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2018-2023)
11.8.5 Roivant Sciences Ltd Recent Development
11.9 TGV-Inhalonix Inc
11.9.1 TGV-Inhalonix Inc Company Detail
11.9.2 TGV-Inhalonix Inc Business Overview
11.9.3 TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.9.4 TGV-Inhalonix Inc Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2018-2023)
11.9.5 TGV-Inhalonix Inc Recent Development
11.10 Therapeutic Systems Research Laboratories Inc
11.10.1 Therapeutic Systems Research Laboratories Inc Company Detail
11.10.2 Therapeutic Systems Research Laboratories Inc Business Overview
11.10.3 Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.10.4 Therapeutic Systems Research Laboratories Inc Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2018-2023)
11.10.5 Therapeutic Systems Research Laboratories Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned: 

Eli Lily
Wockhardt Ltd
Amprologix Ltd
CrystalGenomics Inc
Debiopharm International SA
Destiny Pharma Plc
Lysimmune BioScience
Roivant Sciences Ltd
TGV-Inhalonix Inc
Therapeutic Systems Research Laboratories Inc

License Types: 

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL:/mrrpb5/global-vancomycin-resistant-staphylococcus-aureus-vrsa-infections-market-research-report-2023

Links
[1] /countries/global[2] /healthcare[3] /pharma-healthcare